CTLA4 and metastatic melanoma: In a case report, the combination of anti-CTLA-4 and anti-RANKL was used in a rapidly progressing metastatic melanoma patient with aggressive and symptomatic bone metastases, and no obvious residual lesion was found 62 weeks after diagnosis [88].